ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

10964	Companies
240023	Keywords
168772	Articles
129132	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

BRIEF

published on 06/19/2025 at 15:58, 1 year 2 months ago

Strategic change within OSE Immunotherapeutics

Board Of Directors General Meeting Crossing Thresholds OSE Immunotherapeutics Shareholders' Agreement
PRESS RELEASE

published on 06/19/2025 at 15:53, 1 year 2 months ago

Franchissement de seuils et déclaration d'intention
Déclaration de franchissement de seuils, déclaration d'intention et convention d'actionnaires de OSE Immunotherapeutics. Détails sur les actions et droits de vote

Franchissement De Seuils Action De Concert OSE Immunotherapeutics Déclaration D'intention Pacte D'actionnaires
BRIEF

published on 04/30/2025 at 07:35, 1 year 4 months ago

OSE Immunotherapeutics Presents New Gene Expression Signature at AACR 2025

Immuno-oncology Personalized Treatment Immune Checkpoint Blockade Gene Expression Signature Cancer Prediction
BRIEF

published on 04/30/2025 at 07:35, 1 year 4 months ago

OSE Immunotherapeutics présente une nouvelle signature d'expression génique à l'AACR 2025

Immuno-oncologie Blocage Du Point De Contrôle Immunitaire Signature D'expression Génétique Traitement Personnalisé Prédiction Du Cancer
PRESS RELEASE

published on 04/30/2025 at 07:30, 1 year 4 months ago

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025
OSE Immunotherapeutics and Léon Bérard Cancer Center present a new gene expression signature for predicting clinical response to immune checkpoint at AACR Annual Meeting 2025

AACR Annual Meeting OSE Immunotherapeutics Gene Expression Signature Léon Bérard Cancer Center Clinical Response Prediction
BRIEF

published on 04/09/2025 at 07:35, 1 year 5 months ago

OSE Immunotherapeutics to Present Data on Lusvertikimab at DDW 2025

Ulcerative Colitis OSE Immunotherapeutics Lusvertikimab Phase 2 Extension DDW 2025
BRIEF

published on 04/09/2025 at 07:35, 1 year 5 months ago

OSE Immunotherapeutics présentera des données sur le lusvertikimab au DDW 2025

Rectocolite Hémorragique OSE Immunotherapeutics Lusvertikimab DDW 2025 Extension De La Phase 2
PRESS RELEASE

published on 04/09/2025 at 07:30, 1 year 5 months ago

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
OSE Immunotherapeutics to present new data on Lusvertikimab's long-term benefits and safety in ulcerative colitis at DDW 2025, showcasing potential in autoimmune diseases

Ulcerative Colitis Immuno-oncology Inflammatory Diseases OSE Immunotherapeutics Lusvertikimab
PRESS RELEASE

published on 04/09/2025 at 07:30, 1 year 5 months ago

OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025
OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la Digestive Disease Week (DDW) 2025

Rectocolite Hémorragique OSE Immunotherapeutics Lusvertikimab Anticorps Monoclonal Efficacité Et Sécurité
BRIEF

published on 11/04/2024 at 07:35, 1 year 10 months ago

OSE Immunotherapeutics Reveals Promising Phase 2 Results for Ulcerative Colitis Treatment

Ulcerative Colitis Phase 2 Study OSE Immunotherapeutics Clinical Results Lusvertikimab

Accesswire

Published on 09/11/2026 at 04:00, 7 hours 37 minutes ago

Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 13 hours 12 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 17 hours 51 minutes ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 20 hours 17 minutes ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 20 hours 37 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 10:15, 1 hour 22 minutes ago

TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 09:20, 2 hours 17 minutes ago

Cantourage Expands Portfolio with New Cannabis Active Ingredients for Innovative Compounded Medicines
Published on 09/11/2026 at 09:05, 2 hours 32 minutes ago

ROHM's New High Anti-surge Chip Resistors in "SDR01 Series" Achieve 0.33W Rated Power in 0402 Size
Published on 09/11/2026 at 09:00, 2 hours 37 minutes ago

Homann Holzwerkstoffe publishes its 2026 half-year report
Published on 09/11/2026 at 09:00, 2 hours 37 minutes ago

Picton Property Income Limited - Removal

Les Echos

Published on 09/11/2026 at 07:00, 4 hours 37 minutes ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 4 hours 37 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 4 hours 37 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 4 hours 37 minutes ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 16 hours 7 minutes ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE